{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:06:31Z","timestamp":1794330391202,"version":"4.9.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Mucormycosis has emerged as an increasingly important cause of morbidity and mortality in immunocompromised patients, but the effective drugs for the treatment are limited. Hence, the study aimed to summarize the characteristics of mucormycosis in patients with hematological malignancies, and investigate the efficacy and safety of Amphotericin B Colloidal Dispersion (ABCD) in treating mucormycosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, patients with mucormycosis complicated by hematological malignancies who received ABCD at the First Affiliated Hospital of Zhengzhou University from April 2021 to May 2022 were retrospectively enrolled. The clinical data of the enrolled patients were collected, and then, the drug response at 2 weeks, 4 weeks, and the end of treatment; the survival rate at 4, 8, and 12 weeks; and the laboratory-related indicators and adverse events (AEs) associated with ABCD were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 9 patients with mucormycosis complicated by hematological malignancies were enrolled. The main symptoms were fever, cough, and chest pain. In addition, reversed halo signs (RHS) were found on chest CTs. The responses to ABCD at 2 weeks, 4 weeks, and the end of treatment were 100% (9\/9), 77.8% (7\/9), and 77.8% (7\/9), respectively. The survival rates of the patients at 4, 8, and 12 weeks were 77.8% (7\/9), 66.7% (6\/9), and 66.7% (6\/9), respectively. Among laboratory-related indicators, white blood cell (WBC) counts were significantly increased from baseline after 1 and 2 weeks of ABCD treatment (<jats:italic>P<\/jats:italic>&amp;lt;0.05), whereas neutrophil counts were only increased significantly from baseline at 2 weeks post-treatment (<jats:italic>P<\/jats:italic>&amp;lt;0.05). The most common AEs were infusion-related AEs manifesting as fever, chills, and pruritus. Moreover, none of the patients suffered from renal injury once again.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ABCD is a promising treatment strategy for patients with mucormycosis complicated by hematologic malignancies, showing remarkable efficacy and safety.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2023.1147624","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T05:37:32Z","timestamp":1684301852000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Amphotericin B colloidal dispersion: an effective drug for the treatment of mucormycosis in China"],"prefix":"10.3389","volume":"13","author":[{"given":"Juntao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"B15","doi-asserted-by":"publisher","first-page":"1237125","DOI":"10.1155\/2022\/1237125","article-title":"Clinical manifestations of pulmonary mucormycosis in recipients of allogeneic hematopoietic stem cell transplantation: a 21-case series report and literature review","volume":"2022","author":"Bao","year":"2022","journal-title":"Can Respir J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/myc.12624","article-title":"Prevalence of the reversed halo sign in neutropenic patients compared with non-neutropenic patients: data from a single-centre study involving 27 patients with pulmonary mucormycosis (2003-2016)","volume":"60","author":"Bourcier","year":"2017","journal-title":"Mycoses"},{"key":"B21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1086\/341401","article-title":"A double-blind, randomized, controlled trial of amphotericin b colloidal dispersion versus amphotericin b for treatment of invasive aspergillosis in immunocompromised patients","volume":"35","author":"Bowden","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00920-22","article-title":"Active surveillance program to increase awareness on invasive fungal diseases: the French RESSIF network (2012 to 2018)","volume":"13","author":"Bretagne","year":"2022","journal-title":"mBio"},{"key":"B6","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.rmr.2017.11.009","article-title":"[Retrospective study of 25 cases of pulmonary mucormycosis in acute leukaemia]","volume":"35","author":"Caillot","year":"2018","journal-title":"Rev. Des. maladies respiratoires"},{"key":"B5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1086\/590004","article-title":"Delaying amphotericin b-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis","volume":"47","author":"Chamilos","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"B1","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/s1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European organization for research and treatment of Cancer\/Invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC\/MSG) consensus group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"5018","DOI":"10.1128\/aac.00536-11","article-title":"Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009","volume":"55","author":"Hammond","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s100960100528","article-title":"Treatment of 21 cases of invasive mucormycosis with amphotericin b colloidal dispersion","volume":"20","author":"Herbrecht","year":"2001","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"684 e11","DOI":"10.1016\/j.cmi.2015.03.019","article-title":"Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis","volume":"21","author":"Jung","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"B16","doi-asserted-by":"publisher","first-page":"811.e1","DOI":"10.1016\/j.cmi.2016.03.029","article-title":"Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis","volume":"22","author":"Kyvernitakis","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"B19","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1093\/cid\/cir880","article-title":"A global analysis of mucormycosis in France: the RetroZygo study (2005-2007)","author":"Lanternier","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1056\/NEJMoa1613306","article-title":"A trial of itraconazole or amphotericin b for HIV-associated talaromycosis","volume":"376","author":"Le","year":"2017","journal-title":"New Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.784974","article-title":"Characteristics of mucormycosis in hematological patients and a death prediction model","volume":"12","author":"Ma","year":"2021","journal-title":"Front. Microbiol."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.12.035","article-title":"Has the mortality from pulmonary mucormycosis changed over time? a systematic review and meta-analysis","volume":"27","author":"Muthu","year":"2021","journal-title":"Clin. Microbiol. Infect"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/clinids\/21.5.1145","article-title":"The safety and efficacy of amphotericin b colloidal dispersion in the treatment of invasive mycoses","volume":"21","author":"Oppenheim","year":"1995","journal-title":"Clin. Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1093\/jac\/dkn394","article-title":"Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: data from the patient registry of amphotericin b cholesteryl sulfate complex for injection clinical tolerability (PRoACT) registry","volume":"62","author":"Paterson","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/jof5010026","article-title":"Global epidemiology of mucormycosis","volume":"5","author":"Prakash","year":"2019","journal-title":"J. Fungi (Basel)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1086\/505969","article-title":"Prospective study of amphotericin b formulations in immunocompromised patients in 4 European countries","volume":"43","author":"Ullmann","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"B20","first-page":"635","article-title":"Amphotericin b colloidal dispersion vs. amphotericin b as therapy for invasive aspergillosis","volume":"24","author":"White","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1086\/514672","article-title":"Randomized, double-blind clinical trial of amphotericin b colloidal dispersion vs. amphotericin b in the empirical treatment of fever and neutropenia","volume":"27","author":"White","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jiac.2020.10.005","article-title":"A real-world prospective observational study on the efficacy and safety of liposomal amphotericin b in 426 patients with persistent neutropenia and fever","volume":"27","author":"Yoshida","year":"2021","journal-title":"J. Infect. Chemother."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1147624\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T05:37:37Z","timestamp":1684301857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1147624\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":24,"alternative-id":["10.3389\/fcimb.2023.1147624"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1147624","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fcimb.2023.1147624.s001","asserted-by":"subject"}]},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]},"article-number":"1147624"}}